Factor Xa Inhibitors: Clinical Trials

7 trials of Factor Xa Inhibitors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 recruiting, 1 terminated, 1 unknown. 3 Phase 3, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Completed 1
Not applicable2Completed 1, Terminated 1

Follow Factor Xa Inhibitors: new trials by email Literature Review of Factor Xa Inhibitors trials Research Report on Factor Xa Inhibitors

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
Direct-Acting Oral Anticoagulants (used as per local standard practice) - Traumatic Intracranial Haemorrhage
Phase 3RecruitingWalton Centre NHS Foundation Trust10842025-03-102026-06-18
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy - Cryptogenic Ischemic Stroke, Patent Foramen Ovale
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris7922023-07-072026-03-24
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
Oral Anticoagulant, Direct-Acting - Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions
UnknownClinical Hospital Centre Zagreb12002020-12-152022-04-01
Perioperative Management of Factor Xa Inhibitors
Factor Xa Inhibitor - Atrial Fibrillation, Anticoagulant-induced Bleeding
Not applicableCompletedSeoul National University Hospital25002020-08-042026-08-21
Mild Head Injury, Antiplatelets, and Anticoagulants
direct anticoagulant, antiplatelet drugs, Dicumarols - Craniocerebral Trauma, Cerebral Hemorrhage
CompletedFondazione Policlinico Universitario Agostino Gemelli IRCCS21272019-09-272022-03-31
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
Apixaban, Standard of care - Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement
Phase 3CompletedAssistance Publique - Hôpitaux de Paris15102016-08-262021-02-25
Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation
Drug (Direct thrombin or Factor Xa inhibitor) - Atrial Fibrillation
Not applicableTerminatedAbbott Medical Devices642013-01-012020-08-13

Conditions studied

Atrial Fibrillation (2)  ·  Aortic Valve Stenosis (1)  ·  Cerebral Hemorrhage (1)  ·  Cerebral Hemorrhage, Traumatic (1)  ·  Craniocerebral Trauma (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Foramen Ovale, Patent (1)  ·  Intracranial Hemorrhage, Traumatic (1)  ·  Ischemic Stroke (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (2)  ·  Abbott Medical Devices (1)  ·  Clinical Hospital Centre Zagreb (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Seoul National University Hospital (1)  ·  Walton Centre NHS Foundation Trust (1)

Countries

France (2)  ·  Italy (2)  ·  Croatia (1)  ·  Germany (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Catherine McMahon (1)  ·  Eue-Keun Choi, MD, PhD (1)  ·  Gilles Chatellier, MD (1)  ·  Jean-Louis Mas, MD (1)  ·  Marcello Candelli, MD, PhD (1)  ·  Peter Zimetbaum, MD (1)  ·  Tamara Bozina, PhD (1)

Results publications

PMID 29536857, PMID 29898848, PMID 35583186, PMID 36137682, PMID 38774425, PMID 41520206, PMID 42754280

NIH funding

2015 (1)